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Abstract: Liver transplantation (LT) remains the only therapeutic option offering gold standard treatment for end-stage liver disease
(ESLD) and acute liver failure (ALF), as well as for certain early-stage liver tumors. Currently, the greatest challenge facing LT is the
simple fact that there are not enough adequate livers for all the potential patients that could benefit from LT. Despite efforts to expand the
donor pool to include living and deceased donors, organ shortage is still a major problem in many countries. To solve this problem, the
use of marginal liver grafts has become an inevitable choice. Although the definition of marginal grafts or criteria for expanded donor
selection has not been clarified yet, they are usually defined as grafts that may potentially cause primary nonfunction, impaired function,
or late loss of function. These include steatotic livers, older donors, donors with positive viral serology, split livers, and donation after
cardiac death (DCD). Therefore, to get the best outcome from these liver grafts, donor-recipient selection should be vigilant. Alcoholrelated liver disease (ALD) is one of the most common indications for LT in Europe and North America. Traditionally, LT for alcoholic
liver disease was kept limited for patients who have achieved 6 months of abstinence, in part due to social and ethical concerns regarding
the use of a limited resource. However, the majority of patients with severe alcoholic hepatitis who fail medical therapy will not live
long enough to meet this requirement. Besides, the initial results of early liver transplantation (ELT) without waiting for 6 months of
abstinence period are satisfactory in severe alcoholic hepatitis (SAH). It will be important to take care of these patients from a newer
perspective.
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1. Introduction
Since the first procedure performed by Thomas E. Starzl
in the 1960s, liver transplantation (LT) has become the
gold standard for the treatment of end-stage liver disease
(ESLD), acute liver failure, and some selected liver tumors
[1]. Despite the efforts to increase to donor pool by
increasing the usage of live and deceased donors, there
has been an unmet need for donor livers in the United
States (US) and universally [2,3]. The demand for liver has
been steadily expanding. Only in the US, annually, about
11,000 patients with ESLD get enlisted, while annual liver
transplantations are in the range of 6000–7000 [2]. To
overcome the organ shortage problem, transplantation
centers had to expand their criteria for donor selection.
With the expansion of donor suitability criteria, the use
of marginal grafts has become mandatory. Marginal grafts
or expanded donors are grafts that may potentially cause
primary nonfunction, impaired function, or late loss of
function, although there is not a clear-cut definition [3,4].

In this review we defined marginal grafts as grafts
that carry potential risks of early or late loss of function,
meaning older donors, donors with steatosis, hepatitis,
human immunodeficiency virus (HIV) or split liver, or
donors after cardiac death.
As post-LT survival rates have been steadily
improving, the mean age of donors and recipients
increased with a resulting increase in the use of marginal
donors. Improvements in surgical techniques, advances
in postoperative care, and developments in new
immunosuppressive medications have also contributed to
this. Recent United Network for Organ Sharing (UNOS)
data shows that 1-year post-LT survival is around 85%–
90% and 10-year survival is around 50%.
Before 2002, prioritization of liver transplantation was
performed according to the Child-Turcotte-Pugh score.
This system was based on the presence of subjective criteria
such as ascites and encephalopathy to predict short term
mortality risk. To overcome this hurdle, a more objective
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alternative was the Model for End-Stage Liver Disease
(MELD) score. After the implementation of MELD, waitlist mortality has dramatically declined [5–7]. Besides
this score, the presence of fulminant hepatic failure,
metabolic liver disease, or complications from chronic
liver disease such as variceal bleeding and development
of hepatocellular cancer, are also considerable factors to
proceed with transplantation.
Besides the criteria above, there are some diseases
in which the MELD score is not directly correlated with
survival. These “MELD-exceptions” are hepatocellular
cancer,
hepatopulmonary
syndrome
(HPS),
portopulmonary hypertension (PPH), familial amyloid
polyneuropathy, cystic fibrosis, or cholangiocarcinoma
after chemoradiotherapy protocol. Other considerations,
such as donor age (D-MELD) and frequent cholangitis
episodes in patients with primary sclerosing cholangitis
have been emerging as important factors that predict
prognosis, but they are not MELD-exception points by
consensus yet [8,9]. Recently, serum sodium has also been
included in MELD calculations and used as MELD-Na
(especially in patients with low serum sodium) in the US
[10].
After the final decision on LT, screening and evaluation
of possible comorbidities is of crucial importance for
patients on the transplant waitlist. Even though postLT
survival rates have increased with recent developments
in surgical techniques and medical care, liver recipients
still have lower short-term survival compared to the
age-sex matched general population [11]. Most frequent
complications are due to cardiovascular diseases in
the long-term follow up of liver transplant recipients.
Cardiovascular events comprise almost 19%–42% of
mortalities in this group of patients [12,13]. Mortality rates
increase in ESLD patients who had coronary artery disease
by angiography in the preLT period [14]. Thus, a preLT
evaluation protocol should be able to detect underlying
cardiovascular disease. Single positron tomography,
myocardial perfusion scintigraphy, and dobutamine stress
echocardiography are valuable to evaluate coronary artery
disease. Coronary calcium score (CCS) calculated by
computerized tomography is known to be correlated with
the severity of coronary artery disease and can predict the
cardiovascular risk in ESLD patients [15,16].

and reperfusion injury. These grafts are more vulnerable
to hepatitis C (HCV) recurrence and graft fibrosis and
cirrhosis develop faster [19,20]. Fortunately, the synthetic
capacity of liver is similar in older grafts due to the dual
blood supply [21].
The definition of an older donor shows variability
among different transplantation centers. Age threshold
can change between deceased donor liver transplantation
(DDLT) and living donor liver transplantations (LDLT).
Most studies have defined the age threshold between 65–
70 years in DDLT, while 50–60 years in LDLT [22,23]. One
study calculated liver volumes after LDLT on postoperative
7th day and 3–6 months and compared them with donor
age <30 years versus donor age >50. In patients with donor
age >50, the regenerative capacity of the liver decreased
with age as an independent risk factor [19]. In the case of
LDLT, the condition of the recipient is not the sole problem,
as the donors’ survival and complication rates after
hepatectomy are at least of equal importance. Impaired
regeneration capacity increases morbidity for both the
donor and the recipient. The regeneration problem is not
important in DDLT as the whole liver is used as a graft
[24]. Previous studies have shown that in LDLT donor
age >50 or 60 resulted in lower patient and graft survival
rates if the recipients were older, HCV positive, and their
MELD score was greater than 20 [20,23–26]. Postoperative
complication rates and severity were found to be similar
between donors <50 years of age and donors >50 years of
age [26,27].
A few studies showed that in HCV positive recipients
graft loss and recurrent HCV infection followed by
hepatic fibrosis and development of cirrhosis were faster
when donors were older. A recent consensus held in Paris
recommended not to use older grafts in HCV positive
recipients [22,28,29]. However, at the same time, a cure of
the HCV infection is possible with direct-acting antiviral
drugs. The treatment of HCV infection in live donors
before or after transplantation might enable us to use
older donor grafts in HCV positive recipients. In a short
time, older grafts used in LDLT will potentially result in
better patient and donor survival rates if used in HCV
negative recipients with low MELD scores if they do not
have steatosis or increased ischemia time due to technical
reasons.

2. Donor age
Organ shortage in liver transplantation will potentially
lead to an increased usage of older donors in the future
[17]. In the US, donors aged more than 50, comprise 33%
of donors, while in some European countries this ratio
increases to greater than 50% [18]. The primary problems
with older age donor grafts are impaired regeneration
capacity after transplantation and being prone to ischemic

3. Liver graft steatosis
Hepatic steatosis has 2 subgroups: macro- and
microsteatosis. Microvesicular steatosis is not associated
with poor prognosis after transplantation; in contrast,
macrovesicular steatosis is associated with primary or
early weak donor function [30]. Why does macrovesicular
steatosis lead to poor graft function? Its pathogenesis is
not exactly clear. However, macrovesicular steatosis leads
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to impaired hepatic microcirculation, which makes liver
more susceptible to cold ischemia and ischemia reperfusion
injury [30]. Grafts with lower than 30% steatosis are not
associated with worse posttransplant prognosis. On the
other hand, grafts with 30%–60% steatosis are preferable
when the donor has normal liver functions, the donor is
under 60 years of age, cold ischemia time is below 8 h, with
good graft removal conditions in recipients who meet the
following criteria: HCV negative with a MELD score lower
than 20. In the cases of recipients or donors with greater
than 30% steatosis, the transplant team should consider
the above risks [31].
Liver steatosis is a more important topic in living
LDLT than DDLT since it increases both the donor and
the recipient morbidity due to poorer graft functions
[31,32]. Previous studies showed no relationship between
primary or early poor graft functions and steatosis up
to 30% [33–35]. In mild steatosis up to 60%, both graft
and recipient survival rates with nonsteatotic grafts were
observed if graft volume was higher than 40% of standard
liver volume. Severe liver steatosis affects both graft and
recipient survival rates [36]. Biliary complications were
seen more often in these grafts in the first 3 months after
transplantation. Besides, survival rates of grafts with
severe steatosis (>60%) were significantly shorter and
approximately 25% in 1 year [37]. Similarly, a recent
metaanalysis reported that grafts with moderate to severe
steatosis showed lower survival rates compared to grafts
with no steatosis or mild steatosis. Macrovesicular steatosis
also increases the probability of poor graft functions (PNF)
[30].
Unlike cadaveric liver transplantation, steatosis in
living donors may be reversible. A short-term intense
protein-rich diet, exercise, drugs like fibrates and omega-3
fatty acids may reduce liver steatosis. In some studies,
these methods reduced steatosis successfully in donors
and improved the postoperative outcomes of donors and
recipients [38,39].
4. Obesity
Obesity is on the rise around the world and is threatening
the liver donor pool. According to 2012 data, 69% of the
entire population of the US was overweight (body mass
index [BMI] >25) and 35% was obese (BMI > 30) [40].
Obesity is a known strong risk factor for liver steatosis. In
a study, 76% of BMI > 28 living donors had steatosis in
liver biopsies [41].
Graft steatosis is associated with worse outcomes
in recipients after liver transplantation. These include
ischemia reperfusion injury, biliary strictures, primary
graft failure, and lower survival rates in 1 year [42,43].
Although negative effects of graft steatosis are wellknown effects of obesity alone without steatosis on
liver transplantation are controversial. Recent studies
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reported that in select obese donor groups (BMI ≥ 30 but
≤ 35) of nonsteatotic livers and without accompanying
cardiovascular comorbidities including hypertension,
diabetes mellitus, and dyslipidemia, donor hepatectomy
may be feasible. Both recipients of donors with BMI > 30
and donors had similar outcomes with donors with BMI <
30 in the short and long-term. Obesity is also a risk factor
for postoperative complications. These complications
include pulmonary infections, delayed wound healing
and wound infection, and thrombotic events [44,45]. The
length of hospital stay is longer in obese patients and the
cost of treatment is higher [46].
Knak et al. have observed that people with obesity
without liver steatosis and cardiovascular comorbidities
may safely become donors [47]. Dindo et al. evaluated the
elective surgical results of 6336 patients and reported that
26% were obese. They concluded that obesity was not a
risk factor for postoperative complication rate [48].
5. Chronic hepatitis of grafts
Both donor and recipient infection with hepatitis viruses
affect posttransplant outcomes. Previously, HBV or
HCV positivity in grafts was an exclusion criterion for
transplantation. Along with prophylaxis against hepatitis
B virus (HBV) via the development of HBV vaccine, use
of Hepatitis B immunoglobulin, and use of nucleoside
analogs led to the use of hepatitis B surface antigen
(HBsAg) and hepatitis B core antigen (HBcAg) positive
grafts in liver transplants [49]. Similarly, the development
of direct-acting antiviral agents (DAA) against HCV led to
transplantation of HCV infected liver grafts to both HCV
positive and negative recipients [50].
Grafts in antiHBcAg antibody (HBcAb) positive
donors carry the risk of HBV transmission and most
of these donors have occult HBV infection [51]. After
transplantation of HBcAb-positive grafts, the risk of de
novo HBV (DNHB) infection in HBV-naïve recipients is
58% higher; a lower risk is observed with previous HBV
vaccination or HBV infection (HBsAb+, HBcAb+) [52].
Previous grafts with HBcAb-positive donors were used in
HBV-naïve recipient; DNHB risk was found to be lower in
these recipients with the use of lamivudine [52].
In light of these data, the American Society of
Transplantation (AST) consensus guideline recommends
long term treatment of HBV-naïve recipients with HBcAbpositive donors with nucleoside analogs for prophylactic
purposes [53].
Due to the rapid transmission and progression of HBV
infection in grafts, and because of the loss of 50% of grafts
in 2 years, chronic HBV was a definite contraindication
for liver transplantation in the 1980’s [54,55]. Hepatitis
B immunoglobulin and following antiviral treatment
led to dramatic results in clinical outcomes. Nowadays,
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posttransplant chronic HBV patients have better
outcomes than other transplantation indications [56,57].
Nevertheless, HbsAg-positive grafts without delta hepatitis
and without histologic signs of liver disease are considered
for liver transplantation [58]. Any HBV infected patient
should take antiviral treatment. Posttransplant HBIG
administration is a common practice in transplant centers
depending on recipients’ risk status to keep HBsAb titers
between 100–500 IU/mL [53].
In the aspect of HCV, HCV-positive grafts were
previously only transplantable to HCV-positive recipients
[59,60]. Due to the potential posttransplant transmission
of HCV to the recipient and the course of HCV in
untreated patients, transplantation of HCV positive
grafts is still uncommon [61]. Direct-acting antiviral
agents (DAA) are both very effective in treatment and
well-tolerated in patients with HCV infection. DAA has
success rates above 95% [62]. HCV-positive grafts have
similar graft and recipient survival rates in HCV-negative
recipients if periportal fibrosis (F2 Ishak) is absent during
the pretransplant period [63]. HCV viremia or de novo
HCV infection is detectable by the positivity of HCV RNA
in serum. The mean time for positivity is 1 week after
transplantation [53].
Recurrent HCV infection warrants prompt treatment.
Laboratory, clinical, or histologic findings should
not cause a delay. The choice of DAA depends on the
patients’ immunosuppressive regimen and potential drug
interactions. AST guidelines recommend starting a pangenotypic agent in the early posttransplant period without
delay for genotype analysis [53].
6. Human immunodeficiency virus
The worldwide prevalence of human immunodeficiency
virus (HIV) has reached 37 million [64]. With the
development of antiretroviral treatment, HIV-infected
patients have reached a normal lifetime, and HIVunrelated causes have become major determinants for their
survival [64]. Liver disease is one of the leading causes of
death unrelated to AIDS, reaching 10% [64]. An important
reason for this increased prevalence is a concomitant
infection of HBV and HCV with HIV, reported as more
than 10% and 30%, respectively [64]. Thus, the promotion
of organ transplantation in this population is of great
importance, since the survival rates of HIV-infected
recipients are comparable to noninfected recipients, albeit
with 3 times higher acute rejection rates.
The first efforts to transplant HIV-positive organs were
hampered by the poor outcomes in the 1980’s, resulting
in strict prohibitions in many countries. A decade
later, following the advent of antiretroviral therapies,
a transplant from HIV patients is deemed feasible.
Particularly in countries with high HIV prevalence, liver

transplantation from HIV-positive donors has become an
appealing option. Moreover, nearly two-thirds of HIVpositive patients are willing to donate their organs to HIVpositive recipients. They have unique motivations such as
overcoming HIV-related stigmas and empathy for other
infected patients [65].
Muller from the South African Republic spearheaded
HIV-positive organ transplantation. In his pioneering
series, 27 HIV-infected patients had kidney transplantation
from HIV-infected donors. In these patients, 3- and 5-year
graft and recipient survival rates were found to be similar to
non-HIV infected counterparts. After similar reports from
the United Kingdom and Switzerland [66], HIV Organ
Policy Equity (HOPE) Act passed in the US in 2013. With
this law, the use of HIV-positive organs as grafts has begun
in the US. In March 2016, the first liver transplantation
of an HIV-positive recipient from an HIV-positive donor
was performed at Johns Hopkins University [67]. For
now, HIV-positive organs are transplantable only to HIVpositive patients. First-time transplantation of an HIVpositive organ to an HIV-negative recipient in the world
was in the South African Republic in 2017. In this case, an
HIV-positive mother donated her liver to her baby with
biliary atresia. A special ethics committee decision and
legal permissions were followed by standard transplant
surgery. Before the surgery, the mother had antiretroviral
treatment and the baby had preoperative prophylaxis. One
year after transplantation, both the baby and the mother
were both in good condition. With this transplantation,
the probability of usage of HIV-positive organs in HIVnegative patients is considerable [68], albeit long-term
outcomes remain unclear.
A recent study explored another benefit of the HOPE
act. Every organ is prescreened for HIV antibody and
nucleic acids before pursuing transplantation, however,
these tests are known to have nonnegligible false-positive
rates. Before the act, these organs were unusable if
either one was positive, but with the act, the organs are
transplantable to seropositive recipients. The estimated
number for this organ pool is 50–100 per year in the US
[69].
7. Donor after cardiac death
Since the 1990’s, organs of donors after brain death (DBD)
have been used in many transplantation centers. Organs
of donors after cardiac death (DCD) comprise 5% of all
cadaveric donors [70,71]. Notably, these organ donation
procedures have started right after the determination
of death by cardiorespiratory criteria. The quality of the
donor is the most important factor determining periand posttransplantation organ functions. A metaanalysis
consisting of 25 studies evaluated the outcomes of 62,000
liver transplantation recipients.

1645

METİN et al. / Turk J Med Sci
Ischemic type biliary strictures were commonly
observed in livers from DCD with a reduced total graft
and recipient survival [72]. Although the mechanism of
ischemic cholangiopathy is unclear, possible mechanisms
are longer duration of hot ischemia causing blood stasis
and clots in peribiliary microcirculation [73,74].
8. Split liver grafts
Split liver transplantation (SLT) is the sharing of a liver
of an adult cadaver donor between an adult and a child
recipient. SLT has become an option to increase the
donor pool in child patients. After SLT, complications
such as biliary leaks, biliary strictures, and hepatic artery
thrombosis are more common in adult recipients than
in children in 10 years [75,76]. These complications are
less frequent in further years [77,78]. A successful SLT
depends on 3 factors, including careful recipient and graft
selection, reducing risk factors associated with bad results,
and trying to keep cold ischemia time as short as possible
during liver splitting [79].
9. Severe alcoholic hepatitis
Alcohol-related liver disease (ALD) is the most common
indication of liver transplantation in Europe and the US
[80]. Severe alcoholic hepatitis (SAH) is the presence of
jaundice and hepatic decompensation in individuals who
consume excessive alcohol [81]. Short term mortality of
these patients is high, and 6-month mortality is less than
30% [82,83]. Corticosteroid treatment is useful if not
contraindicated and some patient groups do not respond to
steroid treatment. For these patients, liver transplantation
is the only option [84]. Traditionally, liver transplantation
in ALD patients awaits 6 months of alcohol cessation due
to limited donor pool as well as social and ethical concerns
[81]. Unfortunately, most of these patients cannot survive
even 6 months to complete this abstinence period [81].
Hence, early liver transplantation is considered for severe
alcoholic hepatitis. The first study by Mathurin et al. was
from Europe and included 6 centers from France and 1
center from Belgium between 2005 and 2010. In this
study, 26 patients had liver transplantation and survival
rates have increased significantly at 6 months and 2 years
[83]. Following this article in 2011, 9 patients with SAH
after liver transplantation in the US from Mount Sinai
hospital had similar results [82]. Six-month survival rates
were as high as 89% in transplanted patients [82]. A larger
study from Johns Hopkins including 46 carefully selected
SAH patients who had undergone LT, had similar 1-year
outcomes (97% patient survival and 93% graft survival in
the SAH group) and recidivism (28% in the SAH group)
when compared to 34 patients with more than 6 months
of sobriety [84].
All these studies showed that early liver transplantation
in selected patients with SAH who fail to respond to
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medical treatment may benefit from liver transplantation
with a 6-month survival rate of 77% and 100% [82,84].
The American Consortium of Early Liver
Transplantation for Alcoholic Hepatitis (ACCELERATEAH) group evaluated the results of early liver
transplantation of 147 patients with SAH without
waiting for 6 months of alcohol abstinence period in 12
transplantation centers and reported a 1-year survival rate
of 94%, and 3-year survival rate of 84% (85). Data from
Europe and the US confirm the need for reconsideration
of the rule of 6 months of alcohol abstinence period [80].
Alcohol consumption after liver transplantation
is a major problem for both ALD and SAH. Studies
showed similar rates of reuse of alcohol for early liver
transplantation compared to late transplantation after
6 months of abstinence period. In a prospective study
conducted by Di Martini et al. on 167 patients with
transplantation after 6 months of alcohol abstinence, the
alcohol recidivism rates were 21% and 32% in 1 year and 3
years, respectively [86].
In the American Consortium study by Lee et al. [85],
alcohol recidivism in 147 SAH patients with early LT was
25% and 34% in 1 and 3 years, respectively. Studies showed
similar rates of alcohol relapse in early liver transplantation
(transplantation in 6 months) and transplantation after 6
months of alcohol abstinence period [87]. These studies
support the reconsideration of 6 months of alcohol
abstinence period in ALD. Patients with SAH who failed
to respond to medical treatment have a survival rate of
almost above 80% after liver transplantation. But reuse
of alcohol increases morbidity and graft loss, especially
in heavy drinkers. The major problem is still the reuse of
alcohol in these patients.
10. Conclusion
In this review, we aimed to discuss the requirement for
marginal liver grafts caused by a limited donor pool and
the increasing need for liver transplantation. Marginal
grafts are associated with poor graft outcomes. In light of
the data, careful patient and graft selection may contribute
to better outcomes. The graft pool is insufficient, and
demand is rapidly increasing. Marginal grafts still seem to
be the only option to increase the donor pool. Besides, the
results of early liver transplantation without waiting for
6 months of abstinence period are encouraging in SAH.
Care of such patients needs a newer perspective, especially
for selected groups.
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